PEDF, human recombinant protein
Pigment epithelium-derived factor, PEDF, Serpin-F1, SerpinF1, EPC-1, EPC1, PIG35
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P36955 |
---|---|
Calculated MW | 44.5 kDa |
Gene ID | 5176 |
---|---|
Gene Symbol | PEDF |
Other Names | Pigment epithelium-derived factor, PEDF, Serpin-F1, SerpinF1, EPC-1, EPC1, PIG35 |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE; ≥95% |
Assay2&Purity2 | HPLC; ≥95% |
Recombinant | Yes |
Application Notes | The sterile filtered concentrated (1 mg/ml) protein solution was lyophilized with 20 mM phosphate buffer & 150 mM NaCl pH-7.4. |
Format | Lyophilized protein |
Storage | -20°C; The sterile filtered concentrated (1 mg/ml) protein solution was lyophilized with 20 mM PBS & 150 mM NaCl pH-7.4. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. PEDF is a 50,000 dalton glycoprotein created and secreted in many tissues all the way through the body. A key component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. Additionally, PEDF is capable to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The recognition of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. The unique range of PEDF activities associate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF in addition has the potential to be functional in the treatment of various angiogenesis-related diseases including a number of cancers. Recombinant human PEDF produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 400 amino acids and having a molecular mass of 44.5 kDa.
References
Steele F.R.,et al.Proc. Natl. Acad. Sci. U.S.A. 90:1526-1530(1993).
Tombran-Tink J.,et al.Mol. Vis. 2:11-11(1996).
Yin B.,et al.Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
Kim J.W.,et al.Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.